{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:16:48Z","timestamp":1790889408187,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1093\/schbul\/sbt129","type":"journal-article","created":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T07:43:29Z","timestamp":1380008609000},"page":"1040-1046","source":"Crossref","is-referenced-by-count":61,"title":["Clinical Features of Schizophrenia With Enhanced Carbonyl Stress"],"prefix":"10.1093","volume":"40","author":[{"given":"Mitsuhiro","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Toriumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Niizato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoji","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Itokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,9,23]]},"reference":[{"key":"key\n\t\t\t\t20170512041941_CIT0001","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1523-1755.1999.00302.x","article-title":"Alterations in nonenzymatic biochemistry in uremia: origin and significance of \u201ccarbonyl stress\u201d in long-term uremic complications","volume":"55","author":"Miyata","year":"1999","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170512041941_CIT0002","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/dc10-1087","article-title":"Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study","volume":"34","author":"Nin","year":"2011","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170512041941_CIT0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cardfail.2006.11.009","article-title":"High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure","volume":"13","author":"Koyama","year":"2007","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20170512041941_CIT0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JAD-2002-4203","article-title":"Serum pentosidine as an indicator of Alzheimer\u2019s disease","volume":"4","author":"Meli","year":"2002","journal-title":"J Alzheimers Dis"},{"key":"key\n\t\t\t\t20170512041941_CIT0005","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/2012","article-title":"Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts","volume":"4","author":"Park","year":"1998","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170512041941_CIT0006","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archgenpsychiatry.2010.62","article-title":"Enhanced carbonyl stress in a subpopulation of schizophrenia","volume":"67","author":"Arai","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0007","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1073\/pnas.93.6.2353","article-title":"Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis","volume":"93","author":"Miyata","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170512041941_CIT0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/abio.2002.5638","article-title":"Determination of vitamin B6 vitamers and pyridoxic acid in plasma: development and evaluation of a high-performance liquid chromatographic assay","volume":"305","author":"Bisp","year":"2002","journal-title":"Anal Biochem"},{"key":"key\n\t\t\t\t20170512041941_CIT0009","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0010","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0011","first-page":"751","article-title":"Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome","volume":"155","author":"Buchanan","year":"1998","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0012","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archpsyc.58.10.965","article-title":"Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison","volume":"58","author":"Kane","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0013","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":"Clozapine and \u201chigh-dose\u201d olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison","volume":"63","author":"Kumra","year":"2008","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0014","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170512041941_CIT0016","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/schbul\/17.2.247","article-title":"Update on the clinical efficacy and side effects of clozapine","volume":"17","author":"Safferman","year":"1991","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170512041941_CIT0017","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/070674377301800505","article-title":"Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics","volume":"18","author":"Ananth","year":"1973","journal-title":"Can Psychiatr Assoc J"},{"key":"key\n\t\t\t\t20170512041941_CIT0018","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1192\/bjp.122.2.240","article-title":"Pyridoxine and schizophrenia","volume":"122","author":"Bucci","year":"1973","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0019","first-page":"241","article-title":"Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study","volume":"22","author":"Lerner","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"key\n\t\t\t\t20170512041941_CIT0020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4088\/JCP.v59n1109f","article-title":"Movement disorders and psychotic symptoms treated with pyridoxine: a case report","volume":"59","author":"Lerner","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0021","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.biopsych.2005.10.009","article-title":"Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia","volume":"60","author":"Levine","year":"2006","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0022","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/00207459009000524","article-title":"Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient","volume":"52","author":"Sandyk","year":"1990","journal-title":"Int J Neurosci"},{"key":"key\n\t\t\t\t20170512041941_CIT0023","first-page":"119","article-title":"Negative findings with megavitamins in schizophrenic patients: preliminary report","volume":"1","author":"Ban","year":"1977","journal-title":"Commun Psychopharmacol"},{"key":"key\n\t\t\t\t20170512041941_CIT0024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4088\/JCP.v63n0111","article-title":"Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study","volume":"63","author":"Lerner","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170512041941_CIT0026","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170512041941_CIT0027","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1440-1819.2011.02261.x","article-title":"Idiopathic carbonyl stress in a drug-naive case of at-risk mental state","volume":"65","author":"Arai","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"key":"key\n\t\t\t\t20170512041941_CIT0028","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1176\/appi.ajp.159.7.1080","article-title":"Obstetric complications and schizophrenia: historical and meta-analytic review","volume":"159","author":"Cannon","year":"2002","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170512041941_CIT0029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archpsyc.64.1.31","article-title":"Elevated prenatal homocysteine levels as a risk factor for schizophrenia","volume":"64","author":"Brown","year":"2007","journal-title":"Arch Gen Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/40\/5\/1040\/9349548\/sbt129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T07:41:45Z","timestamp":1503560505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-lookup\/doi\/10.1093\/schbul\/sbt129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,23]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,9,23]]},"published-print":{"date-parts":[[2014,9]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbt129","relation":{},"ISSN":["1745-1701","0586-7614"],"issn-type":[{"value":"1745-1701","type":"electronic"},{"value":"0586-7614","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,23]]}}}